<DOC>
	<DOCNO>NCT00773019</DOCNO>
	<brief_summary>This FDA Condition Approval study include 100 subject 13 US center . Subjects select evaluate plan receive SynchroMed II drug infusion system treatment severe spasticity chronic pain . Subjects must return refill visit 1 , 6 , 12 month . In addition , subject return medically necessary refill . Information collect refill adverse event .</brief_summary>
	<brief_title>SynchroMed II Post-Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<criteria>Have chronic intractable severe spasticity chronic pain require intrathecal delivery medication Have undergo preimplant assessment determine appropriate candidate implantation infusion system Be geographically stable willing return study center followup visit Subject , subject 's legal representative , sign informed consent form prior studyrelated procedure Age least 18 year age time enrollment Have condition pump implant 2.5 cm less surface skin Have ongoing infection prior implant Have insufficient body mass accept pump bulk weight Are unable unwilling adhere study protocol Have estimate life expectancy less twelve month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>infusion pump</keyword>
	<keyword>implantable</keyword>
	<keyword>performance</keyword>
</DOC>